BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 30.75
-0.35 (-1.13%)
Apr 17, 2026, 1:30 PM CST
BioGend Therapeutics Market Cap
BioGend Therapeutics has a market cap or net worth of 3.82 billion as of April 17, 2026. Its market cap has decreased by -3.38% in one year.
Market Cap
3.82B
Enterprise Value
3.33B
Revenue
222.34M
Ranking
n/a
PE Ratio
n/a
Stock Price
30.75
Market Cap Chart
Since June 18, 2019, BioGend Therapeutics's market cap has increased from 2.71B to 3.82B, an increase of 40.89%. That is a compound annual growth rate of 5.14%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 17, 2026 | 3.82B | -19.92% |
| Dec 31, 2025 | 4.78B | 14.21% |
| Dec 31, 2024 | 4.18B | -11.18% |
| Dec 29, 2023 | 4.71B | 109.50% |
| Dec 30, 2022 | 2.25B | -18.50% |
| Dec 30, 2021 | 2.76B | -22.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 18, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Senhwa Biosciences | 4.88B |
| Pharmosa Biopharm | 4.76B |
| Formosa Pharmaceuticals | 4.60B |
| Medigen Biotechnology | 4.25B |
| Sagittarius Life Science | 4.19B |
| ACRO Biomedical | 4.09B |
| Energenesis Biomedical CO.,LTD. | 4.06B |
| Genovate Biotechnology | 3.70B |